Ultragenyx Pharmaceutical Inc. cotiza a 14.92 USD y tiene una capitalización bursátil de $1.5B. En los últimos 12 meses ha facturado $717M con un margen de flujo de caja libre del -70.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic pro…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.90 | $-1.54 | $-1.29 |
| Estimado | $-0.65 | $-1.00 | $-1.46 | $-1.17 |
| Sorpresa | — | +10.0% | -5.5% | -10.3% |
| Métrica | RARE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -79.5% | -38.6% | -40.9% |
| Net Margin | -85.4% | -33.6% | -51.9% |
| FCF Margin | -70.1% | -13.9% | -56.3% |
| ROE | — | -40.4% | — |
| ROA | -37.5% | -32.0% | -5.5% |
| Current Ratio | 2.48 | 2.84 | -0.36 |
| Debt / Equity | — | 0.28 | — |